In Opinion The editorial board writes: The FDA approved a therapy that could cure spinal muscular atrophy. That was cause for hope for hundreds of patients — until Novartis announced the treatment’s price tag: about $2.1 million per patient.
Wow, NYTimes with good ideas to reform the FDA 1. Limit use of AA 2. Cap prices of medicines that come via AA 3. Make sure post market studies happen
Good piece on how to leverage cost containment strategies and evidence for rare disease drugs to ensure effectiveness and access. "Safety, innovation and affordability need not be mutually exclusive goals for cutting-edge treatments." #pricecaps
Opinion | This Drug Will Save Children’s Lives. It Costs $2 Million. $nvs $srpt
via ⁦⁩ TY for the shout-out to the analysis of $NVS error plagued justification for Zolgensma’s price in ⁦
Some additional thoughts on this one
This Drug Will Save Children’s Lives. It Costs $2 Million.
Though I’m not necessarily endorsing the specific proposals, I recommend reading this ⁦⁩ op-ed on drug prices.
This Drug Will Save Children’s Lives. It Costs $2 Million. Safety, innovation and affordability need not be mutually exclusive goals for cutting-edge treatments: editorial #SMA #Zolgensma
This Drug Will Save Children’s Lives. It Costs $2 Million. ‘Accelerated drug approvals involve a clear trade-off for consumers: faster access to potentially lifesaving drugs in exchange for less certainty about how well those drugs work’